Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 36OTHER_GOV 4NIH 3INDUSTRY 3UNKNOWN 2

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 2Genitourinary 1Dermatologic 1

Conditions

Glioblastoma 13Gliosarcoma 11Carcinoma, Non-Small-Cell Lung 10Uterine Cervical Neoplasms 7Adenocarcinoma of Lung 7Pancreatic Neoplasms 6Astrocytoma 6Squamous Cell Carcinoma of Head and Neck 5Rectal Neoplasms 5Lung Neoplasms 5Burkitt Lymphoma 5Breast Neoplasms 5Brain Neoplasms 5Urinary Bladder Neoplasms 4Sarcoma 4Prostatic Neoplasms 4Glioma 4Adenocarcinoma, Bronchiolo-Alveolar 4Vaginal Neoplasms 3Oropharyngeal Neoplasms 3Esophageal Neoplasms 3Triple Negative Breast Neoplasms 2Skin Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Mouth Neoplasms 2Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2

Interventions

Fluorouracil 11Cisplatin 10Radiotherapy 9Paclitaxel 7Trastuzumab 5Erlotinib Hydrochloride 5Specimen Handling 4Taxes 3Radiation 3Nivolumab 3Magnetic Resonance Spectroscopy 3Leucovorin 3Irinotecan 3Carboplatin 3trastuzumab biosimilar HLX02 2entinostat 2alvocidib 2Psychiatric Rehabilitation 2Plicamycin 2PF-05280014 2Oxaliplatin 2Ontruzant 2Ogivri 2Neoadjuvant Therapy 2Microarray Analysis 2Epirubicin 2Decitabine 2Celecoxib 2CT-P6 2Brachytherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Esophageal Neoplasms × Radiation × Clear all
NCT01196390 2026-06-02

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

National Cancer Institute (NCI)

Phase 3 Completed
203 enrolled 22 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT00924027 2025-09-05

A Study of Patients Receiving High-Dose Rate Brachytherapy

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
43 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Biliary Tract Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT03220009 2018-10-03

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicGastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡